US Patent Granted To Chrono Therapeutics Inc. For Its Chrono-Pharmacological Drug Delivery Systems And Applications.
Patent Protection extends at least to 2025
Release Date: 6/2/2010
Download The PDF
Chrono Therapeutics Inc. receives notification from the European Patent Office that an additional key patent for CHRONODOSE™ has been granted. This new patent grant affirms the novelty of CTI’s technology and believes it will considerably reduce any potential risk to the CTI group.
Chrono Therapeutics Inc. is featured in Transdermal Magazine.
(SEE PAGE 6)
Laboratory Facilities
CTI has conducted highly successful and rigorous in-vitro pre-clinical trials at our laboratory in southern NJ. CTI has implemented rigorous in-house product development programs at our facilities.
Our in-house programs have had, as a focus, in vitro and pre-clinical validation testing and micro-engineering optimization of ChronoDose™ subcomponents. CTI has conducted highly successful and stringent quality control tests on ChronoDose’s™ key components.
CTI has also put in place highly effective subcomponent testing and optimization programs. Current and future supply chain management comprising various elements of ChronoDose subcomponents is rigorously tested for efficacy, optimization and consistency with FDA familiarity. An enormous in-house effort has been made to validate-test the efficacy, useful life, robustness, efficiency, and homogeneity of ChronoDose elements from an optimization, efficacy and a quality control perspective.